PCM
KPTI icon

Penserra Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Penserra Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-115
Closed -$10K – 1458
2021
Q3 		$10K Buy
115
+1
+0.9% +$104 ﹤0.01% 1357
2021
Q2 		$17K Buy
114
+1
+0.9% +$145 ﹤0.01% 1186
2021
Q1 		$17K Hold
113
– – ﹤0.01% 987
2020
Q4 		$26K Buy
113
+71
+169% +$16.5K ﹤0.01% 815
2020
Q3 		$9K Buy
+42
New +$10.3K ﹤0.01% 822

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Penserra Capital Management's KPTI Position: Q4 2021 in Review

Penserra Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q4 2021, closing a stake of 115 shares — an estimated $10K sold.

Penserra Capital Management first reported a position in KPTI in Q3 2020 and held it in 5 quarters. The position peaked at $26K in Q4 2020. 143 funds tracked by Wall St. Rank hold KPTI as of Q4 2021.

  • Penserra Capital Management reported no remaining Karyopharm Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 115 Karyopharm Therapeutics shares in Q4 2021, an estimated $10K.
  • Penserra Capital Management first reported a position in Karyopharm Therapeutics in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Karyopharm Therapeutics position peaked at $26K in Q4 2020.
  • 143 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.